Medication info
Telmisartan and Rosuvastatin Tablets 80/10 mg

Telmisartan and Rosuvastatin Tablets 80/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Light orange oval film-coated tablets
Packaging
30 tablets/box [(10 tablets/PTPX3)]
Approval status
Active

MFDS item code 202101796 · Approved 2021.02.23 · Insurance code 643308690

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily as telmisartan; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is coadministered with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is reached 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is developed for patients who need to take both telmisartan and rosuvastatin. Telmisartan is primarily used for the treatment of essential hypertension and plays a role in reducing the risk of cardiovascular diseases. It particularly reduces the risk of myocardial infarction, stroke, and death due to cardiovascular diseases in high-risk patients over 55 years of age who cannot use ACE inhibitors. Rosuvastatin calcium helps to lower blood cholesterol levels in patients with hypercholesterolemia and dyslipidemia, thereby delaying the progression of atherosclerosis. Additionally, it is effective in reducing the risk of stroke, myocardial infarction, and revascularization in patients at high risk for cardiovascular diseases. The combination of these two medications is used to improve cardiovascular health in patients with both hypertension and hyperlipidemia.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily as telmisartan; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is coadministered with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is reached 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious risks to the fetus during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, and nursing mothers should not take this medication and should use appropriate contraceptive methods. It is recommended to avoid the use of this medication in patients with severely impaired liver function or those with biliary obstruction. Patients with muscular disorders or a history of myopathy should also avoid this medication. Administration is contraindicated in patients with severe renal impairment or those taking certain medications. Elderly patients, those with hyperkalemia, and patients with mild to moderate liver dysfunction should use this medication with caution and require regular blood tests and monitoring. If symptoms such as muscle pain, weakness, or cramps occur, medical consultation should be sought immediately, and medication should be discontinued in severe cases. This medication can cause various adverse reactions such as liver dysfunction, hepatitis, and rarely serious skin reactions, so caution is required if symptoms occur. It may interact with other drugs, so be sure to inform the healthcare provider about any medications being taken. Regular monitoring of blood pressure, kidney function, liver function, and potassium levels is necessary during treatment, and immediate action is required if abnormal signs are detected. This medication may cause drowsiness or dizziness when driving or operating machinery, so caution is advised. It is not recommended for children as its safety and efficacy have not been established. In case of an overdose, symptoms such as hypotension, renal failure, and dizziness may occur, requiring immediate medical attention. This medication contains lactose and should not be taken by individuals with specific genetic lactose intolerance.

Side effects

Increased ALT, Increased AST, Elevated serum creatine phosphokinase (CPK), Dizziness, Itching, Dyspepsia, Oral sensory disturbances, Musculoskeletal rigidity, Acne, Nasopharyngitis, Increased serum potassium, Glycosuria, Dysuria, Rhinitis, Oral discomfort, Pulmonary disease, Unspecified gastrointestinal disease, Benign gastrointestinal neoplasms, Hemorrhoids, Skeletal pain, Osteoporosis, Sensory loss, Movement disorders, Atherosclerosis, Frequent urination, Tinnitus, Hearing loss, Bad breath, Fatty liver, Upper respiratory infection, Urinary tract infection, Sepsis, Anemia, Thrombocytopenia, Eosinophilia, Hyperreactivity, Anaphylactic reactions, Hyperkalemia, Hypoglycemia, Depression, Insomnia, Anxiety, Syncope, Visual disturbances, Bradycardia, Tachycardia, Hypotension, Orthostatic hypotension, Dyspnea, Abdominal pain, Diarrhea, Abdominal distension, Vomiting, Abdominal discomfort, Dry mouth, Liver dysfunction, Hepatic impairment, Increased sweating, Rash, Erythema, Angioedema, Drug rash, Toxic skin rash, Eczema, Urticaria, Myalgia, Lumbago, Muscle cramps, Arthralgia, Limb pain, Tendon pain, Acute renal failure, Chest pain, Weakness, Influenza-like illness, Increased serum creatinine, Increased serum uric acid, Elevated liver enzymes, Increased serum CK, Decreased hemoglobin, Headache, Facial spasms, Sensory abnormalities, Paralysis, Cough, Hyperventilation, Pneumonia, Flushing, Erectile dysfunction, Anorexia, Arrhythmia, Weakness, Edema, Decreased libido, Facial edema, Alopecia, Conjunctivitis, Tinnitus, Petechial hemorrhage, Hyperreactive reactions including angioedema, Diabetes, Headache, Constipation, Nausea, Pancreatitis, Itching, Rash, Urticaria, Myopathy, Rhabdomyolysis, Weakness, Polyneuropathy, Amnesia, Peripheral neuropathy, Diarrhea, Thrombocytopenia, Jaundice, Hepatitis, Stevens-Johnson syndrome, Drug reaction with eosinophilia and systemic symptoms syndrome, Lupus-like syndrome, Muscle rupture, Arthralgia, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disorders, Sexual dysfunction, Gynecomastia, Fatal and non-fatal liver failure, Cognitive impairment, Severe muscle weakness, Ocular myasthenia, Hypotension, Tachycardia, Bradycardia, Dizziness, Acute renal failure, Shock, Loss of consciousness, Liver dysfunction, Jaundice, Anaphylactoid symptoms, Interstitial pneumonia, Rhabdomyolysis, Palpitations, Fatigue, Nausea, Insufficient effect, Headache, Cough, Dyspepsia, Palpitations, Myalgia, Increased CK, Constipation, Increased AST, Weakness, Joint pain, Fatigue, Numbness, Sensory abnormalities, Chest discomfort, Nausea, Abdominal pain, Diarrhea, Anorexia, Abdominal distension, Abnormal liver function tests, Syncope, Body pain, Muscle cramps, Gout, Erectile dysfunction, Acute renal failure, Oliguria, Thrombocytopenia, Increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture, and keep it at room temperature between 1 degree and 30 degrees. Proper storage will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Light orange oval film-coated tablets

Package unit

30 tablets/box [(10 tablets/PTPX3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.